Skip to content
10-Q

Quarterly Report

REGENERX BIOPHARMACEUTICALS, INC.

0001104659-21-101442

← back to feed
Filed
Aug 6, 2021 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2021 · Aug 2, 2021 143.45M sh
Cash And Equivalents Q2 2021 · Jun 30, 2021 $2.03M
Cash And Equivalents Q2 2021 · Dec 31, 2020 $427.9K
Current Liabilities Q2 2021 · Jun 30, 2021 $632.95K
Current Liabilities Q2 2021 · Dec 31, 2020 $399.58K
Total Liabilities Q2 2021 · Jun 30, 2021 $3.66M
Total Liabilities Q2 2021 · Dec 31, 2020 $3.38M
Current Assets Q2 2021 · Jun 30, 2021 $2.06M
Current Assets Q2 2021 · Dec 31, 2020 $477.81K
Total Assets Q2 2021 · Jun 30, 2021 $2.11M
Total Assets Q2 2021 · Dec 31, 2020 $551.79K
Shares Diluted Q2 2021 · Jun 30, 2020 133.44M sh
Shares Diluted Q2 2021 · Jun 30, 2020 133.27M sh
Operating Cash Flow Q2 2021 · Jun 30, 2020 −$559.63K
Stockholders Equity Q2 2021 · Jun 30, 2020 −$2.72M
Stockholders Equity Q2 2021 · Mar 31, 2020 −$2.44M
Stockholders Equity Q2 2021 · Dec 31, 2019 −$2.34M
Eps Diluted Q2 2021 · Jun 30, 2020 $0.00
Eps Diluted Q2 2021 · Jun 30, 2020 −$0.01
Eps Basic Q2 2021 · Jun 30, 2020 $0.00
Eps Basic Q2 2021 · Jun 30, 2020 −$0.01
Sga Expense restated Q2 2021 · Jun 30, 2020 $400.95K
Sga Expense restated Q2 2021 · Jun 30, 2020 $757.81K
Rd Expense restated Q2 2021 · Jun 30, 2020 $3.48K
Rd Expense restated Q2 2021 · Jun 30, 2020 $3.95K
Net Income Q2 2021 · Jun 30, 2020 −$436.16K
Net Income Q2 2021 · Jun 30, 2020 −$822.89K
Net Income Q2 2021 · Mar 31, 2020 −$386.73K
Operating Income Q2 2021 · Jun 30, 2020 −$385.24K
Operating Income Q2 2021 · Jun 30, 2020 −$723.38K
Revenue Q2 2021 · Jun 30, 2020 $19.19K
Revenue Q2 2021 · Jun 30, 2020 $38.38K